Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update – Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Sufficient cash on hand to...

Palisade Bio Appoints Margery Fischbein to its Board of Directors Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May ...